ABT vs ZBH: fair value comparison
Abbott Laboratories and Zimmer Biomet Holdings, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZBH currently sits closer to the top of our ranking by discount to fair value.
| ABT | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $99.60 | $89.14 |
| 12-month range | $82.56–$130.59 | $79.58–$103.18 |
| Rank by discount to fair value | #26 of 108 Healthcare | #24 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · ZBH fair value analysis